Two analysts issued Buy ratings and one a Market Perform. Here are the details on the more bearish thesis.
With a leadership team well-experienced in Asia, Singapore-based Aslan is developing varlitinib for regionally prevalent cancers.
“We view ASLN as well-positioned to execute on its clinical strategy with an Asia-focused development platform with multiple shots on goal and a catalyst rich 2H18/2019,” Chang said in a Wednesday note. (See the analyst's track record here.)
Despite the optimism, the analyst said he's waiting for clinical validation for varlitinib in biliary tract cancer and proof of the pan-human epidermal growth factor receptor’s advantage in targeting HER4 before becoming more bullish on the stock.
In the second half of 2018, Aslan is slated to release data from a pivotal varlitinib combination trial in second-line biliary tract cancer; a Phase 1/2 varlitinib combination study in first-line biliary tract cancer; a Phase 2/3 varlitinib combination study in HER1/HER2 co-expressing first-line gastric cancer; and a Phase 2 trial of ASLAN003 in acute myeloid leukemia.
Aslan shares were rallying 23.65 percent to $8.47 at the time of publication Wednesday afternoon.
Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation
HC Wainwright: G1 Therapeutics Is Targeting 'Potential Blockbuster' Oncology Markets
Latest Ratings for ASLN
|May 2018||Leerink Swann||Initiates Coverage On||Market Perform|
|May 2018||BTIG Research||Initiates Coverage On||Buy|
|May 2018||H.C. Wainwright||Initiates Coverage On||Buy|
View More Analyst Ratings for ASLN
View the Latest Analyst Ratings
See more from Benzinga
- Tesla Fixes Model 3 Brakes To Secure Consumer Reports Recommendation
- Credit Suisse Downgrades AbbVie On Humira Competitive Concerns
- Allergan Looks To Sell Women's Health, Infectious Disease Businesses
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.